They operate through non-overlapping mechanisms and are commonly combined in longevity protocols
[1] Other safety considerations include risk of gallbladder disease, pancreatitis, diabetic retinopathy complications (particularly with rapid A1c reduction), and hypersensitivity reactions
Despite the above-mentioned disease burden, there is currently no available FDA- or EMA-approved medication for the disease, although numerous agents have been investigated in preclinical and clinical studies [5]
Now, semaglutide is also prescribed for long term weight management
For example, if you administer two separate drugs, but use three injections to administer them, you would report two injections (96372, 96372-59 Distinct procedural service, and the drug supply codes)